Treatment Options and Clinical Dilemmas in Biochemical Recurrence
Premiere Date: Wednesday, August 4, 2021This activity offers CE credit for:
- Physicians (CME)
- Pharmacists (ACPE)
- ABIM (MOC)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, August 4, 2022
Note: Credit Is No Longer Available
 | Cora N. Sternberg, MD, FACP (Moderator) Clinical Director, Englander Institute for Precision Medicine Professor of Medicine Sandra and Edward Meyer Cancer Center Weill Cornell Medicine New York, NY |
 | Peter R. Carroll, MD, MPH Donna Derr-Chevron Distinguished Professor Taube Family Distinguished Professor in Urology Department of Urology UCSF Helen Diller Family Comprehensive Cancer Center University of California, San Francisco San Francisco, CA |
Biochemically recurrent (BCR) prostate cancer is an increasingly common disease state that has led to increased use of radical prostatectomy for the treatment of high-risk localized disease. Adjuvant radiotherapy (RT) is an underutilized treatment with a better survival advantage, and the American Urological Association, the American Society for Radiation Oncology, and the American Society of Clinical Oncology have expressed support for adjuvant RT. Treatment decisions should be made based on life expectancy, comorbidities, tumor characteristics, and patient preferences.
This CME Outfitters podcast will focus on how clinicians can individualize treatment decisions, based on the use of risk assessment algorithms and advanced imaging techniques with greater ability to detect the sites and extent of disease at BCR. These tools have already demonstrated the ability to change treatment decisions and will substantially impact the management of patients with BCR after radical prostatectomy.
At the end of this CE activity, participants should be able to:
- Stratify patients with early prostate cancer for risk of progression, based on pathological, molecular, and clinical findings.
- Identify optimal treatment strategies in the management of patients with prostate cancer experiencing BCR.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Describe how to stratify patients with early prostate cancer for risk of progression, based on pathological, molecular, and clinical findings.
- Identify optimal treatment strategies in the management of patients with prostate cancer experiencing BCR.
Supported by an educational grant from Astellas and Pfizer, Inc.
Urologists, medical oncologists, PAs, nurse practitioners, and pharmacists
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .5 contact hours (0.005 CEUs) Universal Activity Number:
Enduring: 0376-0000-21-185-H01-P
Type: Knowledge-based
ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Learning Formats
Enduring material
Royal College MOC: Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Note to PAs: PAs may claim a maximum of .5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Sternberg reports that is a consultant for Astellas Pharma US, Inc.; AstraZeneca; Bristol-Myers Squibb Company; Foundation Medicine, Inc.; Immunomedics, Inc./Gilead Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Merck Sharp & Dohme Corp.; National Cancer Institute; Pfizer Inc.; Genentech, Inc./Roche; Sanofi Genzyme; and UroToday.
Dr. Carroll reports that he is on the advisory board for INSIGHTEC; Nutcracker Therapeutics; and Progenics Pharmaceuticals, Inc. He is a stock shareholder (directly purchased) of Nutcracker Therapeutics.
David Modrak, PhD (planning committee) has no disclosures to report.
Evan Luberger (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
CME Outfitters, LLC and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
PD-066-080421-42
